JP2008521538A - 移植可能な器具 - Google Patents
移植可能な器具 Download PDFInfo
- Publication number
- JP2008521538A JP2008521538A JP2007544006A JP2007544006A JP2008521538A JP 2008521538 A JP2008521538 A JP 2008521538A JP 2007544006 A JP2007544006 A JP 2007544006A JP 2007544006 A JP2007544006 A JP 2007544006A JP 2008521538 A JP2008521538 A JP 2008521538A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- chlorophyll
- functional
- chamber
- oxygen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229930002875 chlorophyll Natural products 0.000 claims abstract description 196
- 235000019804 chlorophyll Nutrition 0.000 claims abstract description 196
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 claims abstract description 196
- 244000059219 photoautotrophic organism Species 0.000 claims abstract description 22
- 210000004027 cell Anatomy 0.000 claims description 407
- 239000001301 oxygen Substances 0.000 claims description 172
- 229910052760 oxygen Inorganic materials 0.000 claims description 172
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 170
- 239000000126 substance Substances 0.000 claims description 66
- 210000004379 membrane Anatomy 0.000 claims description 31
- 239000012528 membrane Substances 0.000 claims description 31
- 239000011159 matrix material Substances 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 27
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 claims description 26
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 24
- 239000008103 glucose Substances 0.000 claims description 24
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 20
- 210000004153 islets of langerhan Anatomy 0.000 claims description 17
- 239000000499 gel Substances 0.000 claims description 15
- 239000003102 growth factor Substances 0.000 claims description 15
- 230000002611 ovarian Effects 0.000 claims description 15
- 230000006444 vascular growth Effects 0.000 claims description 14
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 claims description 12
- 238000012544 monitoring process Methods 0.000 claims description 11
- 241000192700 Cyanobacteria Species 0.000 claims description 10
- 238000010521 absorption reaction Methods 0.000 claims description 10
- 210000001124 body fluid Anatomy 0.000 claims description 10
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 10
- 239000001569 carbon dioxide Substances 0.000 claims description 10
- 230000015556 catabolic process Effects 0.000 claims description 10
- 238000006731 degradation reaction Methods 0.000 claims description 10
- 210000005229 liver cell Anatomy 0.000 claims description 10
- 210000001916 photosynthetic cell Anatomy 0.000 claims description 10
- 241000195493 Cryptophyta Species 0.000 claims description 9
- 230000001919 adrenal effect Effects 0.000 claims description 9
- 230000001054 cortical effect Effects 0.000 claims description 9
- 238000002513 implantation Methods 0.000 claims description 9
- 210000002569 neuron Anatomy 0.000 claims description 9
- 230000000849 parathyroid Effects 0.000 claims description 9
- 210000001685 thyroid gland Anatomy 0.000 claims description 9
- 210000003556 vascular endothelial cell Anatomy 0.000 claims description 9
- 230000009471 action Effects 0.000 claims description 8
- 210000000130 stem cell Anatomy 0.000 claims description 8
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 7
- 229940072056 alginate Drugs 0.000 claims description 7
- 235000010443 alginic acid Nutrition 0.000 claims description 7
- 229920000615 alginic acid Polymers 0.000 claims description 7
- 239000010839 body fluid Substances 0.000 claims description 7
- 210000003494 hepatocyte Anatomy 0.000 claims description 7
- 230000003287 optical effect Effects 0.000 claims description 7
- 210000003763 chloroplast Anatomy 0.000 claims description 6
- 238000003860 storage Methods 0.000 claims description 6
- 210000001550 testis Anatomy 0.000 claims description 6
- 238000009792 diffusion process Methods 0.000 claims description 5
- 238000001727 in vivo Methods 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 239000011850 water-based material Substances 0.000 claims description 5
- 229920000936 Agarose Polymers 0.000 claims description 4
- 241000191366 Chlorobium Species 0.000 claims description 4
- 238000005868 electrolysis reaction Methods 0.000 claims description 4
- 239000000017 hydrogel Substances 0.000 claims description 4
- 210000004303 peritoneum Anatomy 0.000 claims description 4
- 238000007920 subcutaneous administration Methods 0.000 claims description 4
- 239000000758 substrate Substances 0.000 claims description 4
- 102000001554 Hemoglobins Human genes 0.000 claims description 3
- 108010054147 Hemoglobins Proteins 0.000 claims description 3
- 241000605118 Thiobacillus Species 0.000 claims description 3
- 239000007789 gas Substances 0.000 claims description 3
- -1 perfluorocarbon compound Chemical class 0.000 claims description 3
- 229920001296 polysiloxane Polymers 0.000 claims description 3
- 241000894006 Bacteria Species 0.000 claims description 2
- 210000001728 clone cell Anatomy 0.000 claims 3
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 22
- 210000003491 skin Anatomy 0.000 description 20
- 229940088597 hormone Drugs 0.000 description 14
- 239000005556 hormone Substances 0.000 description 14
- 102000004877 Insulin Human genes 0.000 description 11
- 108090001061 Insulin Proteins 0.000 description 11
- 229940125396 insulin Drugs 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 10
- 239000000463 material Substances 0.000 description 9
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 239000012510 hollow fiber Substances 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 231100000167 toxic agent Toxicity 0.000 description 4
- 239000003440 toxic substance Substances 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 230000029553 photosynthesis Effects 0.000 description 3
- 238000010672 photosynthesis Methods 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000002381 testicular Effects 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 241000605154 Nitrobacter winogradskyi Species 0.000 description 2
- 208000012868 Overgrowth Diseases 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 230000001651 autotrophic effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000011368 organic material Substances 0.000 description 2
- 239000005416 organic matter Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 150000002926 oxygen Chemical class 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- 229920002126 Acrylic acid copolymer Polymers 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000192707 Synechococcus Species 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 230000005791 algae growth Effects 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000003510 anti-fibrotic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 239000003181 biological factor Substances 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 238000012364 cultivation method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000003372 endocrine gland Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 229920002457 flexible plastic Polymers 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 238000002639 hyperbaric oxygen therapy Methods 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- NPSSWQJHYLDCNV-UHFFFAOYSA-N prop-2-enoic acid;hydrochloride Chemical compound Cl.OC(=O)C=C NPSSWQJHYLDCNV-UHFFFAOYSA-N 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical class FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/022—Artificial gland structures using bioreactors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Transplantation (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Prostheses (AREA)
- Materials For Medical Uses (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/001,556 US8012500B2 (en) | 2000-01-01 | 2004-11-30 | Implantable device |
| PCT/IL2005/001262 WO2006059322A2 (en) | 2004-11-30 | 2005-11-27 | Implantable device |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008521538A true JP2008521538A (ja) | 2008-06-26 |
| JP2008521538A5 JP2008521538A5 (enExample) | 2009-09-03 |
Family
ID=36565437
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007544006A Pending JP2008521538A (ja) | 2004-11-30 | 2005-11-27 | 移植可能な器具 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US8012500B2 (enExample) |
| EP (1) | EP1827490A4 (enExample) |
| JP (1) | JP2008521538A (enExample) |
| CN (1) | CN101123984B (enExample) |
| WO (1) | WO2006059322A2 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011083434A (ja) * | 2009-10-15 | 2011-04-28 | Otsuka Pharmaceut Factory Inc | ガス交換装置 |
| JP2012031070A (ja) * | 2010-07-28 | 2012-02-16 | Otsuka Pharmaceut Factory Inc | 組織の保存方法、及び組織保存装置 |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8012500B2 (en) | 2000-01-01 | 2011-09-06 | Beta-O2 Technologies Ltd. | Implantable device |
| IL134009A (en) * | 2000-01-12 | 2011-07-31 | Bo2 Technologies Ltd | Transplant device |
| US8444630B2 (en) * | 2000-01-12 | 2013-05-21 | Beta-O2 Technologies Ltd. | Oxygen supply for cell transplant and vascularization |
| US20100047311A1 (en) * | 2006-11-22 | 2010-02-25 | Beta O2 Technologies Ltd. | Protecting algae from body fluids |
| WO2008079997A2 (en) * | 2006-12-22 | 2008-07-03 | Medtronic, Inc. | Implantable device, angiogenesis mechanism and methods |
| US8821431B2 (en) | 2007-09-07 | 2014-09-02 | Beta O2 Technologies Ltd. | Air gap for supporting cells |
| US8369942B2 (en) * | 2008-03-20 | 2013-02-05 | The Invention Science Fund I, Llc | Subdermal material delivery device |
| EP2265310A2 (en) * | 2008-04-09 | 2010-12-29 | Microlin, LLC | Transdermal oxygen delivery apparatus and method |
| US9446168B2 (en) | 2010-06-07 | 2016-09-20 | Beta-O2 Technologies Ltd. | Multiple-layer immune barrier for donor cells |
| WO2010032242A1 (en) * | 2008-09-17 | 2010-03-25 | Beta O2 Technologies Ltd. | Optimization of alginate encapsulation of islets for transplantation |
| US8043271B2 (en) | 2008-11-26 | 2011-10-25 | Beta 02 Technologies Ltd. | Apparatus for transportation of oxygen to implanted cells |
| US9357764B2 (en) | 2009-06-18 | 2016-06-07 | Giner, Inc. | System for fluid perfusion of biological matter comprising tissue |
| US10091985B2 (en) * | 2009-06-18 | 2018-10-09 | Giner, Inc. | Perfusing an organ with an in situ generated gas |
| US8784389B2 (en) * | 2009-08-31 | 2014-07-22 | Beta-O2 Technologies Ltd. | Oxygen supply for implantable medical device |
| EP2389958A1 (en) * | 2010-03-22 | 2011-11-30 | Technische Universität Klinikum Rechts der Isar | Use of photosynthetic scaffolds in tissue engineering |
| WO2012176047A1 (en) * | 2011-06-20 | 2012-12-27 | Palti Yoram Prof | Continuous monitoring of glucose and other living body constituents |
| EP2903573A4 (en) | 2012-10-05 | 2016-06-01 | Univ Southern California | IMPLANTABLE OXYGENATOR WITH AUTONOMIC ELECTROLYTE |
| MX384445B (es) | 2013-09-24 | 2025-03-14 | Giner Inc | Sistema para tratamiento con gas de un implante de células. |
| US9950151B2 (en) | 2014-03-27 | 2018-04-24 | Beta-O2 Technologies Ltd. | Implantable medical devices |
| EP4046685A1 (en) | 2014-09-03 | 2022-08-24 | Symbiox, Inc. | Photosynthetic cellular substances and methods of use thereof |
| WO2016059635A1 (en) | 2014-10-13 | 2016-04-21 | Glusense Ltd. | Analyte-sensing device |
| US10137158B2 (en) * | 2015-04-24 | 2018-11-27 | The Board Of Trustees Of The Leland Stanford Junior University | Use of photosynthesis to rebalance ischemia bioenergetics |
| US10883080B2 (en) * | 2015-06-25 | 2021-01-05 | Tokyo Women's Medical University | Method for culturing animal cell composition, method for producing animal cell composition using same, and animal cell composition |
| EP3445872A1 (en) | 2016-04-20 | 2019-02-27 | Glusense Ltd. | Fret-based glucose-detection molecules |
| CA3030536A1 (en) | 2016-07-12 | 2018-01-18 | Micro Green Technologies Ltd. | Compositions comprising microalgae and methods of producing and using same |
| CN110121312A (zh) | 2016-11-03 | 2019-08-13 | 代表亚利桑那大学的亚利桑那董事会 | 有或无外源氧气输送的具有氧气传感器的包封装置的系统 |
| CN116919648A (zh) | 2016-11-03 | 2023-10-24 | 代表亚利桑那大学的亚利桑那董事会 | 有或无氧气输送的堆叠组织包封装置的系统 |
| KR102460378B1 (ko) | 2016-11-03 | 2022-10-27 | 아리조나 보드 오브 리전츠 온 비해프 오브 더 유니버시티 오브 아리조나 | 캡슐화 장치에서 이식 전과 이식 후 세포를 실시간 평가하기 위한 방법 및 시스템 |
| KR20190085961A (ko) | 2016-11-15 | 2019-07-19 | 기너 라이프 사이언시즈, 인크. | 자기 조절형 전기 분해 가스 발생기 및 이를 포함하는 이식 시스템 |
| WO2018093956A1 (en) | 2016-11-15 | 2018-05-24 | Giner, Inc. | Percutaneous gas diffusion device suitable for use with a subcutaneous implant |
| WO2018204867A1 (en) | 2017-05-04 | 2018-11-08 | Giner, Inc. | Robust, implantable gas delivery device and methods, systems and devices including same |
| FR3075831B1 (fr) * | 2017-12-22 | 2020-11-13 | Univ Grenoble Alpes | Dispositif implantable de production d'hydrogene |
| WO2019222273A1 (en) * | 2018-05-14 | 2019-11-21 | Giner Life Sciences, Inc. | System and method for controlling oxygen delivery to implanted cells |
| WO2019222704A1 (en) | 2018-05-17 | 2019-11-21 | Giner Life Sciences, Inc. | Electrolytic gas generator with combined lead and gas port terminals |
| SG11202102910VA (en) * | 2018-09-24 | 2021-04-29 | Procyon Tech Llc | Methods and systems for implantable medical devices and vascularization membranes |
| CA3196876A1 (en) * | 2020-10-30 | 2022-05-05 | Klearchos Papas | Methods and systems for encapsulation devices for housing cells and agents |
| WO2023205302A2 (en) * | 2022-04-20 | 2023-10-26 | Northwestern University | Oxygen generation system and applications thereof |
| CN116585530B (zh) * | 2023-05-05 | 2024-02-02 | 暨南大学 | 一种高效产氧的叶绿体复合水凝胶及其制备方法与应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001050983A1 (en) * | 2000-01-12 | 2001-07-19 | Beta O 2 Technologies Ltd | Implantable device |
| US6368592B1 (en) * | 1998-07-17 | 2002-04-09 | Massachusetts Institute Of Technology | Method of delivering oxygen to cells by electrolyzing water |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2024012B (en) | 1978-04-10 | 1982-07-28 | Johnson & Johnson | Oxygen-generating surgical dressing |
| US4352883A (en) | 1979-03-28 | 1982-10-05 | Damon Corporation | Encapsulation of biological material |
| US4402694A (en) | 1981-07-16 | 1983-09-06 | Biotek, Inc. | Body cavity access device containing a hormone source |
| US4631053A (en) | 1984-03-19 | 1986-12-23 | Taheri Syde A | Oxygenator |
| US4680268A (en) * | 1985-09-18 | 1987-07-14 | Children's Hospital Medical Center | Implantable gas-containing biosensor and method for measuring an analyte such as glucose |
| US5427935A (en) | 1987-07-24 | 1995-06-27 | The Regents Of The University Of Michigan | Hybrid membrane bead and process for encapsulating materials in semi-permeable hybrid membranes |
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| AU5727490A (en) | 1989-06-13 | 1991-01-08 | Agristar, Inc. | Integument and method for culturing and growing organic material |
| US5101814A (en) | 1989-08-11 | 1992-04-07 | Palti Yoram Prof | System for monitoring and controlling blood glucose |
| US5116494A (en) | 1989-08-25 | 1992-05-26 | W. R. Grace & Co.-Conn. | Artificial pancreatic perfusion device with temperature sensitive matrix |
| US5336209A (en) | 1990-04-06 | 1994-08-09 | Porzilli Louis B | Multi-function wound protection bandage and medicant delivery system with simultaneous variable oxygenation |
| US5614378A (en) * | 1990-06-28 | 1997-03-25 | The Regents Of The University Of Michigan | Photobioreactors and closed ecological life support systems and artifificial lungs containing the same |
| US5713888A (en) | 1990-10-31 | 1998-02-03 | Baxter International, Inc. | Tissue implant systems |
| ES2107537T3 (es) | 1991-04-25 | 1997-12-01 | Univ Brown Res Found | Vehiculo inmunoaislante biocompatible implantable para suministrar productos terapeuticos seleccionados. |
| US5391164A (en) | 1991-05-03 | 1995-02-21 | Giampapa; Vincent C. | Subcutaneous implantable multiple-agent delivery system |
| US5545423A (en) | 1991-11-25 | 1996-08-13 | Vivorx, Inc. | Cytoprotective, biocompatible, retrievable macrocapsule containment systems for biologically active materials |
| US5834005A (en) | 1992-02-24 | 1998-11-10 | Encelle, Inc. | Bioartificial devices and cellular matrices therefor |
| US5381075A (en) * | 1992-03-20 | 1995-01-10 | Unisyn | Method and apparatus for driving a flashing light systems using substantially square power pulses |
| US5262055A (en) | 1992-10-19 | 1993-11-16 | The University Of Utah | Implantable and refillable biohybrid artificial pancreas |
| US5433508A (en) * | 1993-10-19 | 1995-07-18 | Tachi-S Co., Ltd | Powered headrest for automotive seat |
| US5651980A (en) | 1994-04-15 | 1997-07-29 | Biohybrid Technologies, Inc. | Methods of use of uncoated gel particles |
| US5529066A (en) | 1994-06-27 | 1996-06-25 | Cb-Carmel Biotechnology Ltd. | Implantable capsule for enhancing cell electric signals |
| US5741334A (en) | 1995-06-07 | 1998-04-21 | Circe Biomedical, Inc. | Artificial pancreatic perfusion device |
| US5792090A (en) | 1995-06-15 | 1998-08-11 | Ladin; Daniel | Oxygen generating wound dressing |
| GB9515807D0 (en) | 1995-08-02 | 1995-10-04 | Cantwell Evelyna D | Topical hyperbaric bandage |
| US5702444A (en) * | 1995-09-11 | 1997-12-30 | Struthers, Mehta And Maxwell | Implantable artificial endocrine pancreas |
| AU6854696A (en) | 1995-09-22 | 1997-04-09 | Gore Hybrid Technologies, Inc. | Improved cell encapsulation device |
| US5855613A (en) | 1995-10-13 | 1999-01-05 | Islet Sheet Medical, Inc. | Retrievable bioartificial implants having dimensions allowing rapid diffusion of oxygen and rapid biological response to physiological change |
| US5855070A (en) | 1997-06-06 | 1999-01-05 | Black & Decker Inc. | Reciprocating saw with pivoted shoe and method for attaching shoe |
| US6148232A (en) | 1998-11-09 | 2000-11-14 | Elecsys Ltd. | Transdermal drug delivery and analyte extraction |
| DE60026974T2 (de) * | 1999-01-04 | 2007-04-19 | Biomm, Inc., Miami | Neue polymerformulierungen, die perfluorierte verbindungen enthalten, zum konstruieren von zellen und geweben zur transplantation, welche den stoffwechsel und das überleben von zellen verbessern, sowie verfahren zu deren herstellung |
| US6562616B1 (en) | 1999-06-21 | 2003-05-13 | The General Hospital Corporation | Methods and devices for cell culturing and organ assist systems |
| US8012500B2 (en) | 2000-01-01 | 2011-09-06 | Beta-O2 Technologies Ltd. | Implantable device |
| US8444630B2 (en) | 2000-01-12 | 2013-05-21 | Beta-O2 Technologies Ltd. | Oxygen supply for cell transplant and vascularization |
| DE10019339B4 (de) * | 2000-04-19 | 2007-03-08 | Heraeus Kulzer Gmbh | Implantat |
| EP1374665A1 (en) | 2001-02-28 | 2004-01-02 | CCS Inc. | Method of cultivating plant and illuminator for cultivating plant |
| US6767342B1 (en) | 2001-04-23 | 2004-07-27 | Evelyna D. Cantwell | Oxygen bandage system |
| AU2002332450A1 (en) | 2001-08-01 | 2003-02-17 | Eric C. Burckle | Artificial pulmonary capillary |
| US7332330B2 (en) | 2001-09-11 | 2008-02-19 | Renamed Biologics, Inc. | Device for maintaining vascularization near an implant |
| AU2003211461C1 (en) | 2002-03-04 | 2008-10-23 | New X-National Technology K.K. | Closed cell culture system |
| US20080119703A1 (en) | 2006-10-04 | 2008-05-22 | Mark Brister | Analyte sensor |
| US8821431B2 (en) | 2007-09-07 | 2014-09-02 | Beta O2 Technologies Ltd. | Air gap for supporting cells |
-
2004
- 2004-11-30 US US11/001,556 patent/US8012500B2/en not_active Expired - Fee Related
-
2005
- 2005-11-27 EP EP05812146A patent/EP1827490A4/en not_active Withdrawn
- 2005-11-27 JP JP2007544006A patent/JP2008521538A/ja active Pending
- 2005-11-27 CN CN2005800473254A patent/CN101123984B/zh not_active Expired - Fee Related
- 2005-11-27 WO PCT/IL2005/001262 patent/WO2006059322A2/en not_active Ceased
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6368592B1 (en) * | 1998-07-17 | 2002-04-09 | Massachusetts Institute Of Technology | Method of delivering oxygen to cells by electrolyzing water |
| WO2001050983A1 (en) * | 2000-01-12 | 2001-07-19 | Beta O 2 Technologies Ltd | Implantable device |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011083434A (ja) * | 2009-10-15 | 2011-04-28 | Otsuka Pharmaceut Factory Inc | ガス交換装置 |
| JP2012031070A (ja) * | 2010-07-28 | 2012-02-16 | Otsuka Pharmaceut Factory Inc | 組織の保存方法、及び組織保存装置 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101123984B (zh) | 2012-11-28 |
| WO2006059322A3 (en) | 2006-07-06 |
| US20050136092A1 (en) | 2005-06-23 |
| US8012500B2 (en) | 2011-09-06 |
| CN101123984A (zh) | 2008-02-13 |
| WO2006059322A2 (en) | 2006-06-08 |
| EP1827490A2 (en) | 2007-09-05 |
| EP1827490A4 (en) | 2012-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8012500B2 (en) | Implantable device | |
| CA2671094C (en) | Oxygen supply for cell transplant and vascularization | |
| US7892222B2 (en) | Implantable device | |
| US10085828B2 (en) | Implantable device with internal air gap for supporting transplanted cells | |
| KR102460406B1 (ko) | 산소 전달을 수반 또는 비-수반하는 적층형 조직 캡슐화 장치 시스템 | |
| WO1991000119A1 (en) | Implantable device | |
| US9950151B2 (en) | Implantable medical devices | |
| EP1786834B1 (en) | Implantable power sources and sensors | |
| An et al. | An atmosphere‐breathing refillable biphasic device for cell replacement therapy | |
| Lim et al. | Functionalized biomaterials-oxygen releasing scaffolds | |
| CN108882697A (zh) | 向移植细胞提供氧气的系统和方法 | |
| EP2806839B1 (en) | Device for the transplantation of cells in suspension | |
| CA3042709C (en) | Stacked tissue encapsulation device systems with or without oxygen delivery | |
| Evron et al. | The Photosynthetic Pancreas: From Fantasy to Reality | |
| Steg et al. | Review on increasing the viability of seeded cells in implanted tissue engineering scaffolds | |
| Lim et al. | A “pancreatic tooth” design best accommodates the limitations of current artificial pancreas technology |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080808 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080808 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090630 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110531 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110829 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110905 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120306 |